Skip to content

Jazz Pharmaceuticals JAZZ Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation

Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation at other companies

SPX Technologies logo
SPX TechnologiesSPXC
$14.6M+49.0%
S&P Global logo
S&P GlobalSPGI
$33M+8.2%
Boston Scientific logo
Boston ScientificBSX
$85M-28.0%
Masco logo
MascoMAS
-$2.5M+71.4%
Two Harbors Investment Corporation logo
Two Harbors Investment CorporationTWO
Popular logo
PopularBPOP

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's share-based payment arrangement, decrease for tax withholding obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's share-based payment arrangement, decrease for tax withholding obligation?
Jazz Pharmaceuticals (JAZZ) reported share-based payment arrangement, decrease for tax withholding obligation of $103.6M in Q1 2026.
How has Jazz Pharmaceuticals's share-based payment arrangement, decrease for tax withholding obligation changed year-over-year?
Jazz Pharmaceuticals's share-based payment arrangement, decrease for tax withholding obligation increased by 54.2% year-over-year, from $67.2M to $103.6M.
What is the long-term trend for Jazz Pharmaceuticals's share-based payment arrangement, decrease for tax withholding obligation?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's share-based payment arrangement, decrease for tax withholding obligation has grown at a 20.6% compound annual growth rate (CAGR), from $35.6M to $75.22M.
What does share-based payment arrangement, decrease for tax withholding obligation mean?
Cash paid by the company to tax authorities to cover employee tax obligations on stock awards.
How do you interpret share-based payment arrangement, decrease for tax withholding obligation?
Higher outflows correlate with increased vesting activity of equity awards, which may signal higher compensation costs or significant employee turnover/retention events.
How does share-based payment arrangement, decrease for tax withholding obligation compare across companies?
Standard cash flow adjustment for companies with significant share-based compensation programs.